{"name":"Nanosonics Limited","slug":"nanosonics","ticker":"NAN","exchange":"ASX","domain":"nanosonics.com","description":"Nuveen New York Quality Municipal Income Fund is a closed ended fixed income mutual fund launched by Nuveen Investments, Inc. The fund is co-managed by Nuveen Fund Advisors LLC and Nuveen Asset Management, LLC. It invests in the fixed income markets of New York. The fund invests in municipal bonds, with a rating of Baa or higher. It employs fundamental analysis, with bottom-up stock picking approach, to create its portfolio. The fund benchmarks the performance of its portfolio against the Standard & Poor's New York Municipal Bond Index and Standard & Poor's National Municipal Bond Index. The fund was formerly known as Nuveen New York Dividend Advantage Municipal Fund. Nuveen New York Quality Municipal Income Fund was formed on May 26, 1999 and is domiciled in the United States.","hq":"Sydney, Australia","founded":2005,"employees":"~1,000","ceo":"Michael Kavanagh","sector":"Medical Devices — Infection Prevention","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":11.53,"stockChange":0.01,"stockChangePercent":0.09,"marketCap":"$368M","metrics":{"revenue":28795244,"revenueGrowth":0,"grossMargin":100,"rdSpend":0,"netIncome":-23149710,"cash":0,"dividendYield":7.5,"peRatio":32,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-02-22","type":"earnings","headline":"Nanosonics Limited Reports Strong Earnings for FY2024","summary":"Nanosonics Limited reported strong earnings for the fiscal year 2024, driven by the success of its EPR technology.","drugName":"","sentiment":"positive"},{"date":"2023-09-01","type":"deal","headline":"Nanosonics Limited Partners with Leading Healthcare Provider","summary":"Nanosonics Limited has partnered with a leading healthcare provider to expand the adoption of its EPR technology.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiugFBVV95cUxQbkVwQlkwbVNCMFdUOUFxdnVQb3VHd3liZF81ck5ZaTdDY09EM3UzWHkwTnMwT0x2bWR0LXEtZy05MzBrU2FUUDlSYVlWR2F1b2JSWU1PcjFuWnp0bWFhdFJER1dyTmJEN2xSVVhVakZ4cm5hRVc1TzNBNTlFRDd6R3p3cWlaX2xoR1lHU3Yyb0RhMlpQTTYzZnBPV2R4VW54QXdCdm5tTW5VakkzLWFOOHNoaVRRampEbWc?oc=5","date":"2025-09-12","type":"regulatory","source":"Stockhead","summary":"Scott Power: ASX health stocks remain under pressure but Telix charts FDA path forward - Stockhead","headline":"Scott Power: ASX health stocks remain under pressure but Telix charts FDA path forward","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizgFBVV95cUxOc1ZWbWxHTG5yeVU1VHFKR0NRaWhzSDM3STJCdTBCRXp3WEVBcHdoQjN4Q3JVQmxkRXBrWGxMckl4cC0yaWdQRlFsTGNGZkNwU3ppZm9zSUdLQlgwVTBtdFZDYUF1cmpZd092ckhyZmhvbkp3c1VndTdFRmVHN2NzY0E3eDhic1hoWmdqeUh0cE93OXFCbExBLXpZX0gtMHNQaWlrY295MDRjTVdhVVYxaDJWNElfTXpVM2lKMVBtTEtqdzJrcmRGZnlxc2w5UQ?oc=5","date":"2025-04-27","type":"pipeline","source":"AFR","summary":"NAN RMD ASX: Billion dollar medical start-ups say Trump could force a US move - AFR","headline":"NAN RMD ASX: Billion dollar medical start-ups say Trump could force a US move","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiUEFVX3lxTE8ySW9lemZiUkVQeGZVdnhVOXhZRXowbUZKY2E2d3c3ckN0Z1dIQ2QxTHZGOXdyOHY5X3ZpZmNOM0JKdWJFMGtHaGFOaU0tZTV6?oc=5","date":"2021-11-27","type":"pipeline","source":"smallcaps.com.au","summary":"ASX Stock Market News | Australian Shares - smallcaps.com.au","headline":"ASX Stock Market News | Australian Shares","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiwFBVV95cUxPYmVxSjMweHJjaTFHZFJabGZvVzV3Q2dNUUdHZ0Y2a2d5bXFnbmJHeHNva0lJOVN2YVA0a0JEdHhqMFBVb3V5ZmstVDJFeEVVN1U3RElxdGgzanI4RWsyM0E0QjRPai00WXVlbUFsX3F6UkxCYzhzNkd3TW1vZlZRbGk5ancyYVVDQWxn?oc=5","date":"2019-09-23","type":"pipeline","source":"intelligentinvestor.com.au","summary":"S&P/ASX 200 Health Care (Sector) - Market Index - Australian Stock Market - intelligentinvestor.com.au","headline":"S&P/ASX 200 Health Care (Sector) - Market Index - Australian Stock Market","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiVEFVX3lxTFA4V0dLbEtyY0hQZVo4WjJyR3AtUGJjTnRwa1daejBUQWhEMGRrU0wwYjRPcXNGWUl6TDctZjV2eklucjJySlJZdmNjZTd1eGJtQXIwbA?oc=5","date":"2017-05-29","type":"pipeline","source":"Yahoo Finance Australia","summary":"Clinuvel Pharmaceuticals Limited (CUV.AX) stock price, news, quote and history - Yahoo Finance Australia","headline":"Clinuvel Pharmaceuticals Limited (CUV.AX) stock price, news, quote and history","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiVEFVX3lxTE1UUEdudldhT1dlNFdhZ3FfQTJpdGdXOUhwM2NGUTh1QWRWN1JWX0dIdFRSRVJZV0VQRkVDOHAzVFNLemU3OThFU2xjdDNFTkVZaEYwTQ?oc=5","date":"2017-05-25","type":"pipeline","source":"Yahoo Finance Singapore","summary":"Mayne Pharma Group Limited (MYX.AX) stock price, news, quote and history - Yahoo Finance Singapore","headline":"Mayne Pharma Group Limited (MYX.AX) stock price, news, quote and history","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":3,"keyCompetitors":["STERIS","Getinge","Stryker"],"therapeuticFocus":["Infection Prevention"],"financials":{"source":"yahoo_finance","revenue":-21984695,"revenuePeriod":"2025-08-31","revenueHistory":[{"period":"2025-08-31","value":-21984695},{"period":"2024-02-29","value":27013668},{"period":"2023-02-28","value":-56831372},{"period":"2022-02-28","value":-731368}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":null,"rdSpendHistory":[],"sgaSpend":1131023,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-23149710,"netIncomeHistory":[{"period":"2025-08-31","value":-23149710},{"period":"2024-02-29","value":25942758},{"period":"2023-02-28","value":-57944459},{"period":"2022-02-28","value":-1815366}],"eps":0.85,"epsHistory":[{"period":"2024-02-29","value":0.85},{"period":"2023-02-28","value":-1.88},{"period":"2022-02-28","value":-0.06}],"cash":0,"cashHistory":[{"period":"2024-02-29","value":0},{"period":"2022-02-28","value":0}],"totalAssets":585076884,"totalLiabilities":247330961,"totalDebt":388631,"equity":337745923,"operatingCashflow":24754332,"operatingCashflowHistory":[{"period":"2025-08-31","value":24754332},{"period":"2024-02-29","value":10862774},{"period":"2023-02-28","value":36958652},{"period":"2022-02-28","value":22406018}],"capex":null,"capexHistory":[],"freeCashflow":24754332,"dividendsPaid":-26207320,"buybacks":-147986,"employees":0,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":11.53,"previousClose":11.52,"fiftyTwoWeekHigh":11.67,"fiftyTwoWeekLow":10.79,"fiftyTwoWeekRange":"10.79 - 11.67","fiftyDayAverage":11.38,"twoHundredDayAverage":11.38,"beta":0.58,"enterpriseValue":0,"forwardPE":0,"priceToBook":1.06,"priceToSales":12.79,"enterpriseToRevenue":0,"enterpriseToEbitda":0,"pegRatio":0,"ebitda":0,"ebitdaMargin":0,"freeCashflow":0,"operatingCashflow":24754332,"totalDebt":244538272,"debtToEquity":72.4,"currentRatio":0.25,"returnOnAssets":0,"returnOnEquity":0,"analystRating":"","recommendationKey":"none","numberOfAnalysts":0,"targetMeanPrice":0,"targetHighPrice":0,"targetLowPrice":0,"dividendRate":0.86,"payoutRatio":2.4,"fiveYearAvgDividendYield":5.52,"exDividendDate":1778803200,"insiderHeldPercent":0,"institutionHeldPercent":14.7,"sharesOutstanding":31947851,"floatShares":0,"sharesShort":158380,"shortRatio":2.89,"shortPercentOfFloat":0.5,"epsTrailing":0.36,"epsForward":0,"revenuePerShare":0.93,"bookValue":10.88,"officers":[],"industry":"Asset Management","irWebsite":"","website":"https://www.nuveen.com/CEF/Product/Overview.aspx?FundCode=NAN&refsrc=vu_nuveen.com/nan","phone":"312 917 7700"}}